Previous research has considered HCP5 to be an oncogene in cervical cancer 26, glioma 27 and follicular thyroid carcinoma 28, while HCP5 downregulation was also found in malignancy like nasopharyngeal carcinoma 29, lung adenocarcinoma 30 and ovarian cancer 31. Here, HCP5 is linked to glioma.